Everything below concerns pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-29. Numbers and descriptions here follow the published literature rather than marketing material.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
The name multiple sclerosis refers to the scars (sclerae – better known as plaques or lesions) that form in the nervous system. These lesions most commonly affect the white matter in the optic nerve, brain stem, basal ganglia, and spinal cord, or white matter tracts close to the lateral ventricles. The function of white matter cells is to carry signals between grey matter areas, where the processing is done, and the rest of the body. The peripheral nervous system is rarely involved. To be specific, MS involves the loss of oligodendrocytes, the cells responsible for creating and maintaining a fatty layer—known as the myelin sheath—which helps the neurons carry electrical signals (action potentials). This results in a thinning or complete loss of myelin, and as the disease advances, the breakdown of the axons of neurons. When the myelin is lost, a neuron can no longer effectively conduct electrical signals. A repair process, called remyelination, takes place in the early phases of the disease, but the oligodendrocytes are unable to completely rebuild the cell's myelin sheath. Repeated attacks lead to successively less effective remyelinations, until a scar-like plaque is built up around the damaged axons. These scars are the origin of the symptoms and during an attack magnetic resonance imaging (MRI) often shows more than 10 new plaques. This could indicate that some number of lesions exist, below which the brain is capable of repairing itself without producing noticeable consequences.
=== Industrial radiography === During World War II, Van de Graaff had used the compact generator invented with Trump to detect defects in ship hulls and ordnance for the U.S. Navy. Drawing on this application, HVEC produced 2-MeV industrial X-ray generators for non-destructive testing of manufactured goods. These units, capable of detecting flaws in thick steel sections, weighed more than two tons and were designed to operate in industrial facilities. HVEC adapted these generators to output electron beams, selling a line of industrial radiography equipment and also renting sterilization services to other companies. In 1957, Ethicon, a medical subsidiary of Johnson & Johnson, purchased an HVEC linear accelerator to sterilize surgical sutures, the first commercial medial product to use radiation processing. Sales of e-beam processing machines picked up after HVEC introduced insulating core transformers. ICTs, operating in the lower-voltage 300 keV to 2.5 MeV range, were used for crosslinking polyethylene and other polymers. W. R. Grace's Cryovac division used radiation crosslinking to produce heat-shrinkable materials for food packaging. Other companies purchased ICTs for extended to wire and cable insulation, rubber vulcanization, auto paint, textile modification, and semiconductors.
The two substrates of this enzyme are dihydrophloroglucinol (1) and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are phloroglucinol (2), reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is dihydrophloroglucinol:NADP+ oxidoreductase. This enzyme participates in benzoate degradation via CoA ligation.
AgNCO + [NH4]Cl → CO(NH2)2 + AgCl This was one of the first artificial syntheses of biological compounds from inorganic starting materials, without the involvement of living organisms. The results of this experiment implicitly discredited vitalism, the theory that the chemicals of living organisms are fundamentally different from those of inanimate matter. This insight was important for the development of organic chemistry. His discovery prompted Wöhler to write triumphantly to Jöns Jakob Berzelius:
== Potential adverse effects == R. serpentina may cause adverse effects by interacting with various prescription drugs or via interference with mechanisms of mental depression or peptic ulcer. The reserpine in R. serpentina is associated with diverse adverse effects, including vomiting, diarrhea, dizziness, headache, anxiety, or hypersensitivity reactions.
Sources: en.wikipedia.org
−O2CC(O)CH2CO2− ⇌ −O2CC(O−)CHCO2− + H+, pKa = 13.03 The enol forms of oxaloacetic acid are particularly stable. Keto-enol tautomerization is catalyzed by the enzyme oxaloacetate tautomerase. trans-Enol-oxaloacetate also appears when tartrate is the substrate for fumarase.
This experience has been described as "the most consequential mescaline trip of the sixties", as it caused Shulgin to redirect his focus and life's work to psychedelic chemistry. Starting in the 1960s, Shulgin synthesized and gradually described hundreds of novel synthetic psychedelics as well as entactogens in scientific publications and published books such as PiHKAL (1991) and TiHKAL (1997). Notable major examples of these drugs have included the DOx psychedelic DOM, the 2C psychedelic 2C-B, and the MDxx entactogen MDMA, among others. However, MDMA was not an original creation of Shulgin's but had previously been first synthesized in 1912 and had surfaced as a recreational drug related to MDA by the mid- to late-1960s. Instead, Shulgin had merely served to help popularize and spread awareness about MDMA and its unique effects. MDMA became outlawed in the mid-1980s. In response to this, the Multidisciplinary Association for Psychedelic Studies (MAPS) was founded by Rick Doblin in 1986 and began efforts to develop MDMA and other psychedelics as medicines. American chemist David E. Nichols has developed numerous novel psychedelics and entactogens from the 1970s to present. Swiss chemist Daniel Trachsel, sometimes referred to as the "German Shulgin", has also developed and published numerous novel psychedelics as well as entactogens since the 1990s. NBOMe psychedelics such as 25I-NBOMe, derived from structural modification of 2C psychedelics, were first described by Ralf Heim and colleagues by 2000.
A DALY (Disability-Adjusted Life Year) is a measure that reflects the total burden of disease. It combines years of life lost (due to premature death) and years lived with disability (adjusted for the severity of the disability). The lower the DALY rates, the lower the burden of endocrine disorders in a country. The map shows that large parts of Asia have lower DALY rates (pale yellow), suggesting that endocrine disorders have a relatively low impact on overall health, whereas some countries in South America and Africa (specifically Suriname and Somalia) have higher DALY rates (dark orange to red), indicating a higher disease burden from endocrine disorders.
Following the contested 2006 presidential election, Felipe Calderón initiated Operation Michoacán, a militarized campaign against drug cartels as an effort to consolidate political authority, strengthen the legitimacy of his administration, and rally public support. Often described as the first major campaign of the conflict, Operation Michoacán marked the beginning of large-scale confrontations between government forces and drug cartels, eventually involving about 45,000 troops together with state and federal police. Calderón's government pioneered a militarized "kingpin strategy" that relied on Mexican Army and Federal Police deployments to capture or kill cartel leaders. This security approach was led by Genaro García Luna (Secretariat of Public Security), Eduardo Medina Mora (Attorney General of Mexico), and Guillermo Galván Galván (Secretariat of National Defense). Early operations included Operation Baja California, Operation Sinaloa, and Operation Chihuahua. Although drug-related violence spiked markedly in contested areas along the U.S. border, such as Ciudad Juárez, Tijuana, and Matamoros, the government was initially successful in detaining and killing high-ranking cartel members, including Alfredo Beltrán Leyva, Arturo Beltrán Leyva, Ignacio Coronel Villarreal, Antonio Cárdenas Guillén, and Vicente Carrillo Leyva. Calderón expressed that the cartels seek "to replace the government" and "are trying to impose a monopoly by force of arms, and are even trying to impose their own laws".
Sources: en.wikipedia.org
In mass spectrometry, the molecular mass of a small molecule is usually reported as the monoisotopic mass: that is, the mass of the molecule containing only the most common isotope of each element. This also differs subtly from the molecular mass in that the choice of isotopes is defined and thus is a single specific molecular mass out of the (perhaps many) possibilities. The masses used to compute the monoisotopic molecular mass are found in a table of isotopic masses and are not found in a typical periodic table. The average molecular mass is often used for larger molecules, since molecules with many atoms are often unlikely to be composed exclusively of the most abundant isotope of each element. A theoretical average molecular mass can be calculated using the standard atomic weights found in a typical periodic table. The average molecular mass of a very small sample, however, might differ substantially from this since a single sample average is not the same as the average of many geographically distributed samples.
In 2024, Lawrence Berkeley National Laboratory published a reliable way to make element 116, livermorium, using a titanium beam to irradiate a plutonium foil. This method may be useful in producing several more elements beyond Oganesson, element 118.
==== Telomerase Vaccines ==== Two telomerase vaccines have been developed: GRNVAC1 and GV1001. GRNVAC1 isolates dendritic cells and the RNA that codes for the telomerase protein and puts them back into the patient to make cytotoxic T cells that kill the telomerase-active cells. GV1001 is a peptide from the active site of hTERT and is recognized by the immune system that reacts by killing the telomerase-active cells.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.